Terms: = Ovarian cancer AND SRSF2, Q01130, 6427, SFRS2 AND Treatment
3 results:
1. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
2. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating srsf2 activity.
Pellarin I; Dall'Acqua A; Gambelli A; Pellizzari I; D'Andrea S; Sonego M; Lorenzon I; Schiappacassi M; Belletti B; Baldassarre G
Oncogene; 2020 May; 39(22):4390-4403. PubMed ID: 32332923
[TBL] [Abstract] [Full Text] [Related]
3. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract] [Full Text] [Related]
